| Literature DB >> 30689193 |
René van Es1, Hans T van den Broek2, Mira van der Naald2, Leon de Jong2,3, Eliane R Nieuwenhuis2,3, Adriaan O Kraaijeveld2, Pieter A Doevendans2,4,5, Steven A J Chamuleau2,5, Frebus J van Slochteren2,4.
Abstract
Comparison of the targeting accuracy of a new software method for MRI-fluoroscopy guided endomyocardial interventions with a clinically available 3D endocardial electromechanical mapping system. The new CARTBox2 software enables therapy target selection based on infarction transmurality and local myocardial wall thickness deduced from preoperative MRI scans. The selected targets are stored in standard DICOM datasets. Fusion of these datasets with live fluoroscopy enables real-time visualization of MRI defined targets during fluoroscopy guided interventions without the need for external hardware. In ten pigs (60-75 kg), late gadolinium enhanced (LGE) MRI scans were performed 4 weeks after a 90-min LAD occlusion. Subsequently, 10-16 targeted fluorescent biomaterial injections were delivered in the infarct border zone (IBZ) using either the NOGA 3D-mapping system or CARTBox2. The primary endpoint was the distance of the injections to the IBZ on histology. Secondary endpoints were total procedure time, fluoroscopy time and dose, and the number of ventricular arrhythmias. The average distance of the injections to the IBZ was similar for CARTBox2 (0.5 ± 3.2 mm) and NOGA (- 0.7 ± 2.2 mm; p = 0.52). Injection procedures with CARTBox2 and NOGA required 69 ± 12 and 60 ± 17 min, respectively (p = 0.36). The required endocardial mapping procedure with NOGA prior to injections, leads to a significantly longer total procedure time (p < 0.001) with NOGA. Fluoroscopy time with NOGA (18.7 ± 11.0 min) was significantly lower than with CARTBox2 (43.4 ± 6.5 min; p = 0.0003). Procedures with CARTBox2 show a trend towards less ventricular arrhythmias compared to NOGA. CARTBox2 is an accurate and fast software-only system to facilitate cardiac catheter therapy based on gold standard MRI imaging and live fluoroscopy.Entities:
Keywords: Hybrid imaging; Image guided therapy; Innovation; MRI; Myocardial viability imaging; Pre-clinical research
Mesh:
Substances:
Year: 2019 PMID: 30689193 PMCID: PMC6428788 DOI: 10.1007/s10554-019-01541-9
Source DB: PubMed Journal: Int J Cardiovasc Imaging ISSN: 1569-5794 Impact factor: 2.357
Fig. 1Experimental study design. A total of 14 animals were subjected to a myocardial infarction, ten animals underwent the injection procedure. Five animals were randomized into the NOGA-arm, whilst 5 animals were randomized to the CARTBox2 group. All ten hearts were embedded and analyzed
Fig. 2CARTBox2 workflow. a The preprocedural steps include the acquisition of an LGE-MRI scan of the left ventricle. The endocardium, epicardium and infarct are then segmented. Using CARTBox2, from these segmentations, the scar transmurality is calculated and projected onto the endocardial surface mesh. Subsequently, the IBZ is calculated and the injection locations are defined and projected onto the mesh (brown arrows), these locations are embedded into the MRI DICOM images. b After acquiring a 3D-RA scan, the MRI DICOM image is fused with the 3D-RA image based on skeletal anatomy. During the injection procedure, the target locations are visualized on the live fluoroscopic images. The AP and RAO images showing the endocardium (red) and target (blue) are visually enhanced for printing purposes. LGE-MRI late gadolinium enhanced magnetic resonance image, IBZ infarct border zone, 3D-RA 3-dimensional rotational angiography, AP anterior-posterior, RAO right anterior oblique
Fig. 4Example of histological analysis. a Photograph of a heart slice after TTC staining. b Schematic impression of the heart slice shown in a, with the myocardium shown in red and the infarct in white. c Fluorescent image of the same heart slice showing the injection deposition in orange. The infarct segmentation is shown in red. The parallel lines indicated the measured distance from injection to the infarct area. d In vivo LGE-MRI scan of the heart. The segmentation was used in CARTBox2, the red line = endocardial border, green line = epicardial border and yellow line = infarct segmentation. e Ex vivo LGE-MRI image of the heart slice shown in figures a–c, which was used to segment the infarct location. f Ex vivo T2* image of the heart slice that was used to confirm the location of the injections found with fluorescent imaging (indicated by red circle). The arrow points towards an air-bubble
Baseline characteristics
| Parameter | NOGA (n = 5) | CARTBox2 (n = 5) | p-value |
|---|---|---|---|
| Body weight (kg) | 72.7 ± 6.4 | 70.5 ± 5.1 | 0.559 |
| LV mass (gr) | 132 ± 14 | 120 ± 19 | 0.309 |
| Infarct size (gr) | 13.4 ± 5.0 | 19.0 ± 5.8 | 0.141 |
| Ejection fraction (%) | 52.6 ± 8.7 | 46.9 ± 4.4 | 0.236 |
| End diastolic volume (ml) | 127 ± 27 | 126 ± 27.5 | 0.950 |
| End systolic volume (ml) | 61 ± 20 | 67 ± 17 | 0.658 |
All parameters except body weight were measured using MRI
Fig. 3Examples of NOGA and CARTBox injection procedure. a Example of a NOGA bipolar voltage map (color scale: 0.5–1.5 mV) in right anterior oblique view, with design line (white) to indicate the infarct border zone. The injections are shown as brown circles. b Anterior-posterior X-ray fluoroscopy image fused with the CARTBox2 modified MRI scan. The left ventricular endocardium (small dots) and the injection target (large dot). c The same image as shown in b, the endocardial wall and catheter are visually enhanced. The arrow indicates the injection target defined on late gadolinium enhanced MRI
Fig. 5Details of injections. a, b The dots represent individual injections with NOGA (n = 40) and CARTBox2 (n = 46). The error bars show the mean and standard deviation of the injections in each animal. a The gray area indicates the infarct area
Injection procedure parameters
| NOGA | CARTBox2 | p | |
|---|---|---|---|
| Injection procedure | |||
| Time (min) | 60.2 ± 16.7 | 69.2 ± 11.9 | 0.355 |
| Total XRF time (min) | 6.1 ± 6.2 | 43.4 ± 6.5 | < 0.001 |
| Total DAP (Gy·cm2) | 11.2 ± 18.0 | 64.2 ± 49.0 | 0.071 |
| PVCs (#)a | 239 ± 100 | 283 ± 10 | 0.42 |
| Non-sustained VTs (#)a | 41.5 ± 11.7 | 74.3 ± 35.0 | 0.13 |
| Per injection | |||
| Time (min/injection) | 5.4 ± 1.8 | 6.0 ± 1.4 | 0.55 |
| Total XRF time (min/injection) | 0.5 ± 0.5 | 3.7 ± 0.8 | < 0.001 |
| Total DAP (Gy·cm2/injection) | 0.9 ± 1.4 | 5.4 ± 3.6 | 0.031 |
| PVCs (#)a | 21.0 ± 7.3 | 20.3 ± 1.1 | 0.86 |
| Non-sustained VTs (#)a | 3.7 ± 0.5 | 5.2 ± 2.1 | 0.21 |
| Total procedure | |||
| Total time (min) | 150.2 ± 12.4 | 69.2 ± 11.9 | < 0.001 |
| Total XRF time (min) | 18.7 ± 11.0 | 43.4 ± 6.5 | 0.003 |
| Total DAP (Gy·cm2) | 29.4 ± 35.7 | 69.8 ± 49.0 | 0.174 |
| PVCs (#)a | 396 ± 138 | 283 ± 10 | 0.20 |
| Non-sustained VTs (#)a | 120 ± 68 | 74.3 ± 35.0 | 0.28 |
DAP dose area product, XRF X-ray fluoroscopy, PVC premature ventricular contraction, VT ventricular tachycardia
aHolter recording and analysis were performed only in the last 8 animals (4 in each group)